CTIC CTI BioPharma

CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. The company concentrates its efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis. In addition, the company has recently started developing pacritinib for use in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. The company's headquartered in Seattle, Washington.

Company profile

Adam Craig
Fiscal year end
Former names
IRS number

CTIC stock data


Investment data

Data from SEC filings
Securities sold
Number of investors


6 May 21
24 Jun 21
31 Dec 21
Quarter (USD)
Mar 21 Dec 20 Sep 20 Jun 20
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 33.11M 33.11M 33.11M 33.11M 33.11M 33.11M
Cash burn (monthly) 2.43M 4M 5.69M 4.41M 5.59M 4.05M
Cash used (since last report) 6.77M 11.16M 15.86M 12.29M 15.59M 11.28M
Cash remaining 26.33M 21.94M 17.24M 20.81M 17.51M 21.83M
Runway (months of cash) 10.8 5.5 3.0 4.7 3.1 5.4

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
1 Apr 21 Partners L P/il BVF Common Stock, par value $0.001 Buy Aquire P No No 2.5 5,171 12.93K 488,879
1 Apr 21 Partners L P/il BVF Common Stock, par value $0.001 Buy Aquire P No No 2.5 950,016 2.38M 3,059,296
1 Apr 21 Partners L P/il BVF Common Stock, par value $0.001 Buy Aquire P No No 2.5 1,044,813 2.61M 4,085,933
1 Apr 21 Partners L P/il BVF Series X1 Convertible Preferred Stock Common Stock, par value $0.001 Buy Aquire P No No 25000 17 425K 17
1 Apr 21 Partners L P/il BVF Series X1 Convertible Preferred Stock Common Stock, par value $0.001 Buy Aquire P No No 25000 239 5.98M 239
1 Apr 21 Partners L P/il BVF Series X1 Convertible Preferred Stock Common Stock, par value $0.001 Buy Aquire P No No 25000 344 8.6M 344
10 Mar 21 Fischer Laurent Stock Option Common Stock Grant Aquire A No No 3.3 80,000 264K 80,000
10 Mar 21 Parkinson David Ross Stock Option Common Stock Grant Aquire A No No 3.3 80,000 264K 80,000
10 Mar 21 Perry Matthew D Stock Option Common Stock Grant Aquire A No No 3.3 80,000 264K 80,000
10 Mar 21 Metzger Michael A Stock Option Common Stock Grant Aquire A No No 3.3 80,000 264K 80,000

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders
Current Prev Q Change
Total holders 0 0
Opened positions 0 0
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares
Current Prev Q Change
Total value 0 0
Total shares 0 0
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Largest transactions
Shares Bought/sold Change

Financial report summary

Management Discussion
  • Research and development expenses. Our research and development expenses for compounds under development and preclinical development were as follows (in thousands):
  • Costs for our compounds include external direct expenses such as principal investigator fees, charges from contract research organizations, or CROs, and contract manufacturing fees incurred for preclinical, clinical, manufacturing and regulatory activities associated with preparing the compounds for submissions of NDAs or similar regulatory filings to the FDA, the EMA or other regulatory agencies outside the United States and Europe, as well as upfront license fees for acquired technology. Operating expenses include our personnel costs and an allocation of occupancy, depreciation and amortization expenses associated with developing our compounds. We are not able to capture the total cost of each compound because we do not allocate operating expenses to all of our compounds. Cumulative to date external direct costs incurred by us as of March 31, 2021 were $191.4 million for pacritinib (excluding costs for pacritinib prior to our acquisition of certain assets from S*BIO in May 2012 and $29.1 million of in-process research and development expenses associated with the acquisition of certain assets from S*BIO).
  • Research and development expenses increased to $9.4 million for the three months ended March 31, 2021 compared to $3.3 million for the same period in 2020. The increase between the three-month periods ended March 31, 2021 and 2020 was primarily attributable to a $1.4 million increase in costs related to the PACIFICA Phase 3 trial, a $3.2 million increase in regulatory and other costs, which include activities related to rolling NDA submission for pacritinib, and a $1.5 million increase in costs related to the PRE-VENT Phase 3 trial.
Content analysis
H.S. sophomore Avg
New words: abatement, add, aGvHD, allogeneic, Brian, Center, graft, GvHD, harbor, hematopoietic, HLA, host, Joseph, LLC, Masonic, matched, merger, Minnesota, Moffitt, par, PhD, Pidala, promulgated, staffing, uncollectability, University, unpaid, wording
Removed: abroad, abuse, abusive, academic, accelerate, acceleration, accentuated, accept, acceptability, acceptable, accident, accidental, accomplish, achieved, acquiring, adequacy, adequate, administer, administered, Advancing, advantage, advertised, advertising, affecting, affiliated, afford, aforementioned, aggressive, agree, agreed, allegation, alleged, alternative, altogether, America, analytical, announced, applicant, applied, approvability, approvable, approve, area, arise, arm, arranging, assert, asserted, asserting, assertion, assessed, assist, attainment, attempt, attempting, attention, authorization, authorize, authorizing, avoid, awarded, aware, baseline, behalf, beneficially, bid, biosimilar, biotechnology, blocker, board, brand, breadth, breakdown, bribery, bringing, broad, brought, budget, burdensome, buy, capacity, cardiovascular, carried, carry, carrying, catastrophic, Celgene, cessation, cGMP, chain, challenge, challenged, charter, chemical, chemotherapy, China, CHMP, choice, choose, Circuit, circumvented, circumventing, circumvention, civil, claim, claimed, clearance, cleared, clinically, code, collected, commence, commercialized, committee, commonly, community, comparator, comparison, compassionate, compensate, compensatory, compete, competition, complementary, complexity, complicating, complied, complying, composition, comprehensive, comprise, compromise, computer, concentration, conclusion, confidence, confidential, confidentiality, confirmatory, conflict, consistently, consolidate, constitute, constituting, constitutionality, constrained, consumer, consuming, consummate, consummated, consummation, contact, contamination, context, continuation, continuing, continuity, controlled, controlling, conventional, Conversely, core, corporation, correction, corrupt, costly, counterfeit, country, cover, coverage, covering, create, created, creditor, criminal, criteria, criticizing, curtail, curtailment, custom, customer, cybersecurity, damage, damaged, dated, death, debarment, decide, decided, decline, decreasing, dedicate, deductible, defend, defense, deferred, deficiency, defray, Delaware, delayed, delaying, deliver, denial, denote, deny, denying, Department, depending, deploy, derivation, derivative, Description, designated, desire, destruction, detect, detecting, deter, deterioration, determination, determined, deterring, difficulty, diligence, dilute, diminish, directed, directing, Directive, disagree, disaster, disclose, discontinuation, discontinue, discounting, discovered, discovery, disposal, dispose, disposing, disputed, disrupt, disrupted, disruption, disruptive, distraction, distribute, district, diversification, diversion, divert, diverted, document, dollar, domestic, domestically, dose, dosing, downgrade, downturn, drop, duration, EAP, earn, earned, earthquake, easier, economically, economy, education, educational, effort, electronic, eligibility, elimination, embodied, emergency, employed, employee, employment, enacted, encounter, encountered, enforce, enforcement, enforcing, enroll, enrolling, environmental, epidemic, error, established, estimable, euro, eventual, evolve, exceed, exceeding, excessive, exchangeable, exclude, exclusion, Exclusive, exclusively, exclusivity, execution, exhausted, exit, expanded, expanding, expedite, expensive, experienced, experimental, expertise, expiration, expire, expired, explicitly, explosion, export, exposure, extended, extensive, extreme, extremely, faced, facilitate, factual, failing, fall, false, fast, favor, FCPA, FDCA, February, fedratinib, fewer, fiduciary, Finally, fire, float, flood, flow, fluctuated, fluid, force, forgo, formally, forward, fraud, free, frequency, frequent, frequently, fully, furlough, furnishing, gain, gaining, gather, GCP, GDP, generic, genetic, geopolitical, Gilead, globally, GLP, good, govern, governing, governmental, greater, guarantee, guide, halt, halting, hamper, handling, harmful, harmonization, heavily, heightened, hematological, high, higher, hinder, HIPAA, hire, history, honored, identifiable, identify, IDMC, illegal, illegally, immigration, impacted, impair, impairing, impermissibly, implementation, implemented, implementing, importance, important, importing, impose, imposed, imposition, impossible, improper, improve, improvement, inability, inadequate, inadvertently, incentive, incident, inclined, inconclusive, inconsistency, incorporated, incorporating, increasing, increasingly, incumbent, incurring, IND, indefinite, independent, independently, indirect, indirectly, individual, individually, induce, ineffective, infected, inflation, influenced, infringe, infringed, infringement, infringer, inherent, initially, initiating, initiation, injunctive, injury, innovation, inopportune, input, Inrebic, inside, insider, instability, installation, instituted, institutional, insufficient, insurance, insurer, intangible, integrating, integrity, intended, intense, intention, intentional, interested, interference, intermediate, internally, international, internationally, interplay, interpret, interrupt, interruption, intolerant, introduced, introduction, intrusion, invalidated, inventory, invest, invested, investigation, involved, involving, IRB, Italy, Jakafi, Jakavi, judicial, July, justify, key, Kingdom, knowingly, labeling, labor, laboratory, lack, large, larger, launched, laundering, lawsuit, leadership, learned, legislation, legislative, length, lengthy, letter, leverage, liable, licensed, licensor, light, likelihood, Likewise, limiting, listing, living, local, located, logistical, lose, low, MAA, maintained, maintaining, maintenance, managerial, managing, mandate, manufacture, manufactured, manufacturer, marketability, marketable, marketed, Marketplace, mature, maturity, meaningful, media, Medicaid, Medicare, Member, merge, merit, met, mezzanine, microliter, misappropriation, misconduct, misleading, mitigation, modification, modified, momelotinib, monetary, monitoring, motivate, multinational, mutual, narrow, narrowed, narrowing, narrowly, national, natural, necessitated, negatively, negotiating, noncompliance, North, notification, notified, notify, occur, offered, Office, offset, oncology, operational, operator, opportunity, opt, opted, ordinary, organization, organizational, origin, original, originating, orphan, outage, outbreak, output, outweigh, overriding, oversee, owe, packaging, partially, partnership, party, past, patent, paying, people, percent, percentage, perception, performing, permanent, permanently, person, perspective, pertaining, pharmacy, physician, PIXUVRI, platelet, point, policy, political, postpone, power, practice, practicing, precluded, predicted, premium, preparatory, prescription, preserve, prevail, prevent, prevented, previously, pricing, privacy, proactively, processing, procurement, produce, produced, production, productivity, progression, prohibit, prohibiting, prohibitively, projection, prolonged, promoted, promoting, promotion, promotional, prompt, promptly, properly, proportionate, proposal, proprietary, prosecuting, prosecution, prospective, protected, protecting, provoke, proxy, PTO, publicity, publicly, publish, purpose, pursued, pursuing, put, qualify, qualifying, quality, quickly, radiation, radioactive, range, ranged, rapid, rapidly, realized, recall, receipt, receivable, receiving, recent, recession, recommend, recommended, recoup, recovery, recruit, redesign, refer, reference, referendum, referral, refinancing, refund, refusal, regain, regained, registration, regular, regularly, regulating, reimbursement, rejected, rejection, relate, reliable, relied, relief, relinquish, remain, remediate, remediation, removal, remove, removed, remuneration, rendered, repay, repeat, repeated, replace, replaced, replacing, repurchase, reputation, requirement, requiring, reserve, residence, resolve, resolved, resolving, respond, responding, Restated, restoration, restrict, restructuring, resulted, retaining, retention, reviewed, revised, revocable, revocation, routine, royalty, ruled, ruling, ruxolitinib, safeguarding, salt, sample, satisfactory, satisfy, scaling, scientific, scope, Seattle, secondary, secret, section, secure, seeking, seizure, selected, selling, senior, Separately, separation, serve, Servier, serving, settlement, shareholder, shelf, shipping, short, shortage, show, showing, shut, shutdown, side, Sierra, significance, similarly, site, small, soliciting, sooner, sophisticated, sourced, specific, speculation, speculative, spend, spread, stability, stated, stating, statute, statutory, stay, stemming, stockholder, stolen, stop, storage, store, stored, strain, strategy, strictly, strong, struggle, studying, subjecting, submitted, subordinated, subpart, subpoena, subscription, subsequently, successor, sudden, suffer, sufficiently, suggest, suit, suitable, Summary, Sunshine, supplier, supporting, surgery, surrogate, surveillance, suspended, suspension, system, team, technical, technological, telecommunication, temporarily, temporary, terrorism, Teva, theft, thrombocythemia, tied, tighter, timeline, toxicity, track, Trademark, train, training, transferred, transition, translation, transmission, transmit, transparency, transplant, transport, transportation, travel, traveling, treat, treating, treble, trend, TRISENOX, Trump, turn, typically, UK, unallocated, unanticipated, unapproved, unauthorized, unconstitutional, undesirable, uneconomical, unenforceable, unexpected, unfit, unknown, unmanaged, unpatented, unpredictable, unrest, untitled, upheld, user, valid, validated, validation, validity, valuable, valuation, variability, varying, vendor, vera, verify, view, violating, violation, volatile, volatility, voluntarily, voluntary, voted, war, warehousing, warning, warrant, Washington, waste, weaken, weakening, weather, week, weigh, whistleblower, wholesale, wide, widespread, willfully, willingly, withdraw, withdrawal, withdrew, work, workforce, world, wrongfully, Wuhan, yield